BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Genocea announces pricing of $36,750,000 public offering of common stock

20 June 2019 | News

The gross proceeds from the offering are expected to be $36,750,000 before deducting underwriting discounts and commissions and offering expenses payable by Genocea.



Genocea Biosciences, a biopharmaceutical company developing personalized cancer immunotherapies has announced the pricing of its previously announced underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $3.50 per share, before underwriting discounts and commissions. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the public offering price per share, less the underwriting discounts and commissions. The gross proceeds from the offering are expected to be $36,750,000 before deducting underwriting discounts and commissions and offering expenses payable by Genocea. All of the shares are being sold by Genocea. The offering is expected to close on or about June 24, 2019, subject to satisfaction of customary closing conditions.

SVB Leerink and Stifel are acting as joint book-running managers for the offering. Baird and Needham & Company are acting as co-managers for the offering.

A registration statement on Form S-1 relating to the offering was filed with and declared effective by the Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus included in the registration statement declared effective by the SEC.

Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Its unique ATLAS technology platform allows identifying immunotherapy targets based on each person’s tumor antigen-specific T cell responses. It is advancing complementary programs built from ATLAS insights: GEN-009, a neoantigen vaccine candidate for which they are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, a neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020.